New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
about
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meetingAnalysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cellsEffect of HM910, a novel camptothecin derivative, on the inhibition of multiple myeloma cell growth in vitro and in vivo.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaCurrent Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.An update on the role of daratumumab in the treatment of multiple myeloma.Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.Systemic virotherapy for multiple myeloma.Emerging drugs and combinations to treat multiple myeloma.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.Nanotherapeutics for multiple myeloma.
P2860
Q28075816-C7DED981-8F5A-4D68-AB9E-D7C26CD09CDDQ31119290-7AF34351-6ED5-4CDC-A4AC-B007D38D5417Q33992425-BE951D77-AAD4-4F5A-B25C-0567B60A2E8CQ35666414-B0E104D9-7EF4-4A8B-A223-4FCA36B97520Q37666309-A0D72C9C-541B-4EB0-8310-B9010AD829EAQ38202691-0DE674A3-4434-4D70-B25A-8CA0F89CE2ECQ38775700-D31D8E6A-8965-4AEB-A30C-87B600126CF9Q39146499-C8DAAF81-5426-45CA-8774-8DD122064FC6Q40087770-E599B004-4720-4110-9161-79593C518D6CQ41694198-1D1C4D5F-EEB2-494E-A1E2-20F5B7D4D25FQ48958626-D398FDE0-9855-4432-9368-A1BC1F6F23EDQ52559684-F435964A-998E-415B-BEC6-C1BF4245A26F
P2860
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
New developments in the manage ...... ory multiple myeloma patients.
@en
New developments in the manage ...... ory multiple myeloma patients.
@nl
type
label
New developments in the manage ...... ory multiple myeloma patients.
@en
New developments in the manage ...... ory multiple myeloma patients.
@nl
prefLabel
New developments in the manage ...... ory multiple myeloma patients.
@en
New developments in the manage ...... ory multiple myeloma patients.
@nl
P2860
P1476
New developments in the manage ...... ory multiple myeloma patients.
@en
P2093
Henk M Lokhorst
Niels W C J van de Donk
P2860
P304
P356
10.1517/14656566.2013.805746
P407
P577
2013-05-31T00:00:00Z